Table 4 Patient demographic, clinical and treatment characteristics, National Cancer Data Base 2010–2017 Adjuvant vs Neoadjuvant Chemotherapy, Patients ≥70 with cT1-3/cN0-3, Triple Negative or HER2 Positive invasive breast cancer treated with surgery and/or chemotherapy (N = 1203)
Value or no. of patients (Column %) | |||
|---|---|---|---|
Surgery followed by chemotherapy (n = 917) | Chemotherapy followed by surgery (n = 286) | p-Value | |
Age (median, range), years | 75 (71–90) | 74 (71–90) | 0.09 |
Clinical T Stage (cT) | <0.001 | ||
T1 | 379 (41.33%) | 45 (15.73%) | |
T2 | 483 (52.67%) | 196 (68.53%) | |
T3 | 55 (6%) | 45 (15.73%) | |
Clinical N Stage (cN) | <0.001 | ||
N0 | 669 (72.96%) | 166 (58.04%) | |
N1 | 204 (22.25%) | 98 (34.27%) | |
N2 | 32 (3.49%) | 13 (4.55%) | |
N3 | 12 (1.31%) | 9 (3.15%) | |
Year of diagnosis | <0.001 | ||
2010 | 84 (9.16%) | 10 (3.5%) | |
2011 | 77 (8.4%) | 17 (5.94%) | |
2012 | 86 (9.38%) | 18 (6.29%) | |
2013 | 102 (11.12%) | 26 (9.09%) | |
2014 | 112 (12.21%) | 21 (7.34%) | |
2015 | 105 (11.45%) | 54 (18.88%) | |
2016 | 152 (16.58%) | 67 (23.43%) | |
2017 | 199 (21.7%) | 73 (25.52%) | |
HER2 | 0.21 | ||
Negative | 459 (50.05%) | 131 (45.8%) | |
Positive | 458 (49.95%) | 155 (54.2%) | |
ER | 0.96 | ||
Negative | 624 (68.05%) | 195 (68.18%) | |
Positive | 293 (31.95%) | 91 (31.82%) | |
PR | 0.85 | ||
Negative | 700 (76.34%) | 218 (76.22%) | |
Positive | 216 (23.56%) | 68 (23.78%) | |
Unknown | 1 (0.11%) | 0 | |
Hormone Receptor | 0.87 | ||
Negative | 614 (66.96%) | 190 (66.43%) | |
Positive | 303 (33.04%) | 96 (33.57%) | |
Triple Negative | 0.21 | ||
No | 458 (49.95%) | 155 (54.2%) | |
Yes | 459 (50.05%) | 131 (45.8%) | |
CCDMa | 0.90 | ||
2 | 641 (69.9%) | 201 (70.28%) | |
3 | 276 (30.1%) | 85 (29.72%) | |
